CYLD (human), pAb



BML-PW0760-0025	25 µl	92.00 USD

BML-PW0760-0100	100 µl	325.00 USD

Product Specification

Purity Detail:	Purified by salt precipitation.

Formulation:	Liquid. In PBS containing 0.01% sodium azide.

Immunogen:	Synthetic peptide corresponding to aa 336-353 of human CYLD.

Source/Host:	From rabbit.

Specificity:	Recognizes human CYLD.

Application:	Western Blot (1:1’000) Optimal conditions must be determined individually for each application.

Short Term Storage:	-20°C

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 1 year after receipt when stored at -20°C. Dilute with PBS, pH 7.2-7.4, containing 1% normal goat serum (if a goat anti-rabbit IgG linker antibody is to be used). Store diluted antibody at +4°C, do not freeze and use within 1 month.

Handling:	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Miscellaneous/General:	The tumor suppressor CYLD is a deubiquitinylating enzyme (DUB) that antagonises NF-κB and JNK signaling by disassembly of Lys⁶³-linked ubiquitin chains synthesised in response to cytokine stimulation. The DUB activity of CYLD is mediated by its C-terminal ubiquitin specific protease (USP) domain, pathogenic truncations and mutations of which are associated with the hypertrophic skin tumor cylindromatosis through disruption of the USP domain and subsequent loss of CYLD catalytic activity.

Figure: Detection of CYLD in HeLa S100 cytosolic fraction (Prod. No. BML-SW8750, 10µg) by Western blotting using PAb to CYLD (human) (Prod. No. BML-PW0760) at 1:5000 dilution.

Please mouse over

General Literature References

Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains: D. Komander, et al.; EMBO Rep. 10, 466 (2009), Abstract;

The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module: D. Komander, et al.; Mol. Cell 29, 451 (2008), Abstract;

Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells: W. Jin, et al.; J. Biol. Chem. 282, 15884 (2007), Abstract; Full Text

CYLD in ubiquitin signaling and tumor pathogenesis: F. Ikeda & I. Dikic; Cell 125, 643 (2006), Abstract;

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members: E. Trompouki, et al.; Nature 424, 793 (2003), Abstract;

Identification of the familial cylindromatosis tumour-suppressor gene: G.R. Bignell, et al.; Nat. Genet. 25, 160 (2000), Abstract;